FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | View Sample | Privacy

ImmunoCellular gains brain cancer vax patent

Free Newsletter

FierceVaccines is a weekly update on the vaccine industry, with a special focus on the innovations revolutionizing the development and production of vaccines. Join thousands of lab research professionals who get FierceVaccines via weekly email. Sign up today!



Tools

Los Angeles-based biotech ImmunoCellular Therapeutics has received a patent for its glioblastoma vaccine, ICT-107. The patent, named "System and method for the treatment of cancer, including cancers of the central nervous system," protects ImmunoCellular's dendritic cell-based vaccine combined with chemotherapy, according to Pharmaceutical Business Review.

"This patent has applicability to multiple types of cancer, including our first clinical target, glioblastoma," said president and CEO, Manish Singh, according to Proactive Investors. The vaccine is produced using cancer stem cells and targets tumor-associated antigens.

One year ago, ImmunoCellular released some surprising Phase I trial results, with an 80 percent two-year survival rate and 44 percent progression-free survival rate. The company is currently conducting a Phase II trial and has increased the number of sites from 15 to 20 or more, Proactive Investors reports.

- here's the Proactive Investors post
- see the PBR article

Related Article:
Brain cancer vax promising in PhI


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceVaccines Email Newsletter:

More stories about ImmunoCellular Therapeutics   cancer vaccine   brain cancer